Abstract: FR-PO1230
Efficacy and Safety of Pegmolesatide on Post-Transplant Anemia in Kidney Transplant Recipients: A Retrospective Comparative Cohort Study
Session Information
- Transplantation: Clinical - Rejection, Biomarkers, and Pharmacology
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Transplantation
- 2002 Transplantation: Clinical
Authors
- He, Yuanzhen, West China Hospital of Sichuan University, Chengdu, Sichuan, China
- Yang, Binqi, West China Hospital of Sichuan University, Chengdu, Sichuan, China
- Yang, Hong-Yu, West China Hospital of Sichuan University, Chengdu, Sichuan, China
- Jing, Rui-Ying, West China Hospital of Sichuan University, Chengdu, Sichuan, China
- Shi, Yun-Ying, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Background
Posttransplantation anemia (PTA) is common in kidney transplant recipients, but comparative data guiding optimal pharmacotherapy are limited. This real world study provides the first head to head comparison of Pegmolesatide (a novel long acting ESA) versus Roxadustat (a HIF PHI) for PTA management.
Methods
In this single center retrospective cohort study, 63 consecutive PTA patients received either subcutaneous Pegmolesatide 4 mg once every four weeks (n=27) or oral Roxadustat 100-150mg thrice weekly with dose adjustment based on hemoglobin levels (n=36) according to physician discretion. Hb, serum creatinine, eGFR and iron parameters were measured at baseline and multiple follow up time points. Adverse events were recorded.
Results
Despite lower baseline Hb and eGFR in the Pegmolesatide group, Hb rose steadily in both cohorts. The primary outcome—percentage Hb change at three months—was significantly greater with Pegmolesatide (33.0±16.8% vs. 23.8±11.2%; P=0.014). This advantage was accentuated in patients with active infection (41.3±13.9% vs. 17.5±14.9%; P=0.006). Multivariable linear regression, adjusting for treatment assignment, age, BMI, baseline Hb, baseline eGFR, albumin, baseline proteinuria, transferrin, and infection status, confirmed treatment assignment as an independent predictor of hemoglobin response. Graft function remained stable in both groups and no treatment related adverse events were reported.
Conclusion
Pegmolesatide provided superior shortterm Hb correction over Roxadustat in PTA patients, especially in those with concomitant infection. These findings warrant validation in larger prospective trials.
Funding
- NIDDK Support